Cardiovascular implants — Endovascular devices —
Part 1:
Endovascular prostheses

Implants cardiovasculaires — Dispositifs endovasculaires —
Partie 1: Prothèses endovasculaires
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Foreword</td>
<td>iv</td>
</tr>
<tr>
<td>Introduction</td>
<td>v</td>
</tr>
<tr>
<td>1. Scope</td>
<td>1</td>
</tr>
<tr>
<td>2. Normative references</td>
<td>1</td>
</tr>
<tr>
<td>3. Terms and definitions</td>
<td>2</td>
</tr>
<tr>
<td>4. Intended performance</td>
<td>3</td>
</tr>
<tr>
<td>5. Design attributes</td>
<td>3</td>
</tr>
<tr>
<td>5.1 General</td>
<td>3</td>
</tr>
<tr>
<td>5.2 Delivery system</td>
<td>4</td>
</tr>
<tr>
<td>5.3 Implant</td>
<td>4</td>
</tr>
<tr>
<td>6. Materials</td>
<td>4</td>
</tr>
<tr>
<td>7. Design evaluation</td>
<td>5</td>
</tr>
<tr>
<td>7.1 General</td>
<td>5</td>
</tr>
<tr>
<td>7.2 Delivery (and/or endovascular) system</td>
<td>5</td>
</tr>
<tr>
<td>7.3 Implant</td>
<td>11</td>
</tr>
<tr>
<td>7.4 Preclinical in vivo evaluation</td>
<td>19</td>
</tr>
<tr>
<td>7.5 Clinical evaluation</td>
<td>22</td>
</tr>
<tr>
<td>8. Manufacturing</td>
<td>25</td>
</tr>
<tr>
<td>9. Sterilization</td>
<td>25</td>
</tr>
<tr>
<td>9.1 Products supplied sterile</td>
<td>25</td>
</tr>
<tr>
<td>9.2 Products supplied non-sterile</td>
<td>26</td>
</tr>
<tr>
<td>9.3 Sterilization residuals</td>
<td>26</td>
</tr>
<tr>
<td>10. Packaging</td>
<td>26</td>
</tr>
<tr>
<td>10.1 Protection from damage in storage and transport</td>
<td>26</td>
</tr>
<tr>
<td>10.2 Marking</td>
<td>27</td>
</tr>
<tr>
<td>10.3 Information supplied by the manufacturer</td>
<td>27</td>
</tr>
<tr>
<td>Annex A (informative) Attributes of endovascular devices—Technical</td>
<td>29</td>
</tr>
<tr>
<td>and clinical considerations</td>
<td></td>
</tr>
<tr>
<td>Annex B (informative) Bench and analytical tests</td>
<td>36</td>
</tr>
<tr>
<td>Annex C (informative) Definitions of reportable clinical events</td>
<td>39</td>
</tr>
<tr>
<td>Bibliography</td>
<td>42</td>
</tr>
</tbody>
</table>
Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2.

The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights.

ISO 25539-1 was prepared by Technical Committee ISO/TC 150, Implants for surgery, Subcommittee SC 2, Cardiovascular implants.

ISO 25539 consists of the following parts, under the general title Cardiovascular implants — Endovascular devices:

— Part 1: Endovascular prostheses
— Part 2: Vascular stents
— Part 3: Vena cava filters
Introduction

This part of ISO 25539 has been prepared in order to provide minimum requirements for endovascular prostheses and the methods of test that will enable their evaluation. It is the first part of a proposed three-part International Standard. ISO/TS 15539, from which this part of ISO 25539 is derived, serves as a rationale for the requirements. The Technical Specification was developed by first identifying the design requirements for endovascular implants and listing the potential implant and clinical failure modes. Tests were then identified to address each of the failure modes. The requirements provided in this part of ISO 25539 are based on that assessment.

Due to the variations in the design of implants covered by this part of ISO 25539 and in some cases due to the relatively recent development of some of these implants, acceptable standardized in vitro tests and clinical results are not always available. As further scientific and clinical data become available, appropriate revision of this part of ISO 25539 will be undertaken.
Cardiovascular implants — Endovascular devices —

Part 1:

Endovascular prostheses

1 Scope

1.1 This part of ISO 25539 specifies requirements for endovascular prostheses, based upon current medical knowledge. With regard to safety, it gives requirements for intended performance, design attributes, materials, design evaluation, manufacturing, sterilization packaging and information supplied by the manufacturer. It should be considered as a supplement to ISO 14630, which specifies general requirements for the performance of non-active surgical implants.

1.2 This part of ISO 25539 is applicable to endovascular prostheses used to treat arterial aneurysms, arterial stenoses, or other appropriate vascular abnormalities.

1.3 This part of ISO 25539 is applicable to delivery systems if they comprise an integral component of the deployment of the endovascular prostheses.

1.4 This part of ISO 25539 is not applicable to vascular occluders, with the exception of contra-lateral iliac occluders when used as an integral part of an aorto-uni-iliac device. See ISO 14630 for excluded products.

1.5 This part of ISO 25539 is not applicable to procedures and devices used prior to the introduction of the endovascular system (defined in 3.6), such as balloon angioplasty devices.

2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 7198:1998, Cardiovascular implants — Tubular vascular prostheses

ISO 11134:1994, Sterilization of health care products — Requirements for validation and routine control — Industrial moist heat sterilization

ISO 11135:1994, Medical devices — Validation and routine control of ethylene oxide sterilization

ISO 11137:1995, Sterilization of health care products — Requirements for validation and routine control — Radiation sterilization

ISO 10993 (all parts), Biological evaluation of medical devices

ISO 11607:1997, Packaging for terminally sterilized medical devices

ISO 13485, Medical devices — Quality management systems — Requirements for regulatory purposes

ISO 13488:1996, Quality systems — Medical devices — Particular requirements for the application of ISO 9002

ISO 14155 (all parts), Clinical investigation of medical devices for human subjects
3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 7198 and ISO 14630 and the following apply.

3.1 attachment system
system integral to the endovascular prosthesis that is designed to interface directly with vessel wall in order to prevent migration

NOTE The system may also prevent blood flow on the outside of the prostheses at the attachment sites.

3.2 delivery system
system or mechanism used to deliver the endovascular prosthesis to the targeted position

NOTE The delivery system is removed after implant placement.

3.3 determine
quantitatively appraise or analyse

3.4 endoleak
persistence of blood flow outside the lumen of an endovascular prosthesis but within an aneurysm sac or adjacent vascular segment being treated by the graft

NOTE Endoleaks are categorized as follows:
- a Type I endoleak is periprosthetic and occurs at the proximal or distal attachment zone;
- a Type II endoleak is caused by retrograde flow from patent branch arteries, for example lumbar and intercostal;
- a Type III endoleak arises from a defect in the graft material or from an inadequate seal between modular graft components;
- a Type IV endoleak is due to graft permeability, often identified by a generalized blush of contrast within the aneurysm sac.

3.5 endovascular prosthesis
endovascular graft
endovascular implant
transluminally placed vascular prosthesis, residing partially or completely within a vascular conduit to form an internal bypass or shunt between sections of the vascular system
3.6 endovascular system
system used to treat a vascular lesion from within the vessel, typically comprised of an endovascular prosthesis and its delivery system

NOTE 1 An abdominal aortic aneurysm is an example of a vascular lesion which can be treated with an endovascular system.

NOTE 2 For the purposes of this part of ISO 25539, the delivery system as well as the implant are included within this definition.

3.7 evaluate
qualitatively appraise or analyse

3.8 graft material
non-metallic component of the endovascular prosthesis

3.9 reportable clinical events
complications or failures that may be observed with clinical use of the endovascular system

4 Intended performance
The requirements of Clause 4 of ISO 14630:1997 shall apply.

5 Design attributes

5.1 General
The requirements of Clause 5 of ISO 14630:1997 shall apply. In addition, the following shall be taken into account:

a) with regard to oxidation potential: the possibility of crevice corrosion passivation level over the relevant parts;

b) with regard to wear: fretting corrosion;

c) with regard to interface between implant and body:
   1) fixation hooks if present;
   2) relative movement between implant and tissue;
   3) forces exerted by the device on the surrounding tissue;
   4) forces required to deform the implant if the deformation is permanent;

d) expected ingrowth, penetration, perforation, tilting and migration;

e) introduction and delivery systems.

NOTE These additional items are adapted from Clause 5 of EN 12006-3:1998.
5.2 Delivery system

The design attributes to meet the intended performance of the delivery system shall additionally take into account at least the following:

a) the ability of the system to permit consistent, accurate and safe access to the intended location;
b) the ability of the system to permit consistent, accurate and safe deployment of the implant;
c) the ability of the system to permit consistent and safe withdrawal of the delivery system;
d) the compliance of the system with the requirements of ISO 10993-1 and appropriate other parts of the ISO 10993 series;
e) the ability of the system to minimize blood loss (haemostasis);
f) the visibility of the system under fluoroscopy or other technologies.

5.3 Implant

The design attributes to meet the intended performance of the implant shall additionally take into account at least the following:

a) the ability of the implant to be consistently, accurately and safely deployed;
b) the ability of the implant to ensure effective fixation within the vasculature;
c) the ability of the implant to maintain adequate integrity;
d) the ability of the implant to prevent blood from flowing through the implant wall as appropriate to its intended use;

Changes in wall permeability after implantation shall be taken into account.

e) the appropriate interaction between and among the modules of endovascular systems designed with modular components (modularity);
f) the consistency of the implant dimensions and its design for compatibility for use in specified vessel diameters;
g) the ability of the implant to maintain adequate blood flow through the lumen (patency);
h) the compatibility of the implant with exposure to magnetic resonance imaging (MRI) fields;
i) the compliance of the implant with the requirements of ISO 10993-1 and appropriate other parts of the ISO 10993 series;
j) the visibility of the implant under fluoroscopy or other technologies.

6 Materials

The requirements of Clause 6 of ISO 14630:1997 shall apply. Additional testing specific to certain materials should be performed to determine the appropriateness of the material for use in the design. For example, Nitinol materials dependent on shape-memory properties should be subjected to testing in order to assess transformation properties.
7 Design evaluation

7.1 General

The requirements of Clause 7 of ISO 14630:1997 shall apply. A risk analysis shall be carried out in accordance with the requirements of ISO 14971.

NOTE All testing may not be appropriate for all prosthesis designs.

Justification shall be provided for the properties not measured for characterization.

It is impossible to take into consideration all future and emerging technologies. These emerging-technology prostheses will need to follow the basic test protocols of this part of ISO 25539 to characterize the endovascular system. Testing beyond the scope of this part of ISO 25539 may also be necessary to characterize new emerging-technology prostheses. Consideration shall be given to the failure modes of the prostheses and their effects on the performance of the implant in identifying the appropriate testing. For compound prostheses, as defined in ISO 7198:1998, 3.9, although it may be appropriate to conduct some of the testing described in this part of ISO 25539 on components of the prosthesis, testing of the endovascular system as a whole is also required. In addition, if the compound prosthesis is partially constructed of a resorbable component, the non-resorbable portion of the implant shall be characterized as well as the implant as a whole.

Each segment of a composite prosthesis, as defined in ISO 7198:1998, 3.8, shall be tested. In addition, any manufactured anastomosis shall satisfy the requirements of this part of ISO 25539 relating to leakage and factory anastomotic strength.

Retesting shall be performed whenever significant changes are made in materials, construction, configuration, application, or processing methods.

A complete description of the validated test methods and sample preparation procedures used to address the requirements of this part of ISO 25539 shall be documented by the manufacturer. The method and sample size chosen shall be justified. Where acceptance criteria are not specified, the manufacturer shall evaluate the acceptability of the results against predetermined criteria.

For certain design attributes, the use of a reference device should be considered.

If it can be justified that sterilization has no effect on the characteristics of the device that are under evaluation, the required tests may be carried out on non-sterilized devices.

7.2 Delivery (and/or endovascular) system

7.2.1 Ability to access

7.2.1.1 General

The ability of the system to permit safe, consistent and accurate access to the intended location shall be evaluated.

Hazards to be evaluated include, but are not limited to, the following:

a) guidewire not crossing the lesion;

b) introducer and delivery systems not matching the access site (i.e. size mismatch);

c) delivery system not advancing to target site;

d) emboli generation;

e) implant dislodgement.